Skip to main content
  • Site Image

    Single Cell Analysis Facility now available to CCR investigatorsCCR investigators now have access to new Single Cell Technologies through the SCAF in Building 37 (Room 1042) ...Read More

  • Site Image

    NIH IRP Collaborative Research ExchangeCCR investigators now have access to new Single Cell Technologies through the SCAF in Building 37 (Room 1042) ...Read More

  • Site Image

    DEPArray Technology for Rare Cell IsolationThis automated platform enables users to identify and recover specific individual cells of interest from complex, heterogeneous samples for downstream genomic analysis. ...Read More

  • Site Image

    NCI Capabilities in Next Generation DNA SequencingThe CCR has access to capabilities in the area of Next Generation DNA Sequencing through laboratories including the CCR Sequencing Facility, the Laboratory of Molecular Technology, and the CCR Genomics Core. ...Read More

  • Site Image

    The CCR Bioinformatics Training and Education Program (BTEP)The CCR Bioinformatics Training and Education Program has the objective of assisting and enabling CCR researchers with the management and analysis of the massive amounts of data emerging out of experiments relating to hi...Read More

New Technologies, Scientific Resources

The Office of Science and Technology Resources (OSTR) identifies, evaluates and makes available new technologies and scientific resources to NCI's Center for Cancer Research (CCR) investigators through partnerships, collaborations, contracts and other technology transfer agreements with outside organizations, including the private sector.


OSTR-Supported Technologies in CCR Publications

In this manuscript, we review the performance and applications of a novel capillary nano-immunoassay (CNIA) system (The Simple Western System™, marketed by ProteinSimple, CA, USA), a fully automated capillary electrophoresis system for characterization of proteins and their post-translational modifications. This new system overcomes many of the limitations of conventional proteomic approaches: it offers straightforward target specific detection, easy operation, high quality data quantitation and excellent assay reproducibility using nanogram levels of sample. This technology has been successfully applied in the dissection of signaling pathways, assessment of proteomic biomarkers, and evaluation of targeted therapies.
Cataisson et al. found that cutaneous SCC was associated with high amounts of hepatocyte growth factor (HGF), which activates the receptor MET. In transgenic mouse models, HGF and oncogenic RAS each activated a common downstream transcriptional program in skin cells, resulting in stimulation of the epidermal growth factor receptor (EGFR) pathway through the production and secretion of its ligands. Furthermore, established squamous tumors in mice regressed when this activation of or signaling by this EGFR pathway was blocked. In some human SCCs, high HGF and activated MET correlated with an EGFR-activating gene signature like the one identified in the mice, indicating that this pathway may offer therapeutic targets for patients.

The NCI-60 was the first cancer cell line database established and it remains the largest drug and most complete source of molecular data (12, 13). In the current study, we provide whole genome methylation levels from 485,577 probes across the NCI-60 cancer cell line panel. We detail probes that are associated with genes, and provide easy access to them using our CellMiner\Cell line signature web-based application (14). This allows direct comparison and integration with other molecular and activity data, examples of which are included. We also provide a novel form of visualization of the level of influence on gene transcript levels of DNA methylation and copy number, and examples of the relevance of DNA methylation for predicting the activity of DNA-targeted agents.

Calendar of Events

No upcoming events


Go to top